IL-5
IL-5 is a central cytokine regulating eosinophil differentiation, survival, and activation. Its receptor-specific signaling underlies both disease pathogenesis and therapeutic interventions, including monoclonal antibodies and receptor agonists for experimental models.
References:
- [1]. Philbin VJ, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol. 2012 Jul;130(1):195-204.e9. [Content Brief]
- [2]. Elias M, et al. IL-36 in chronic inflammation and fibrosis - bridging the gap? J Clin Invest. 2021 Jan 19;131(2):e144336. [Content Brief]
- [3]. Queen D, et al. Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development. Front Cell Dev Biol. 2019 Dec 4;7:317. [Content Brief]
- [4]. Wagener BM, et al. Synergistic Inhibition of β2-adrenergic Receptor-mediated Alveolar Epithelial Fluid Transport by Interleukin-8 and Transforming Growth Factor-β. Anesthesiology. 2015 May;122(5):1084-92. [Content Brief]
- [5]. Boutet MA, et al. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential. Int J Mol Sci. 2019 Mar 13;20(6):1257. [Content Brief]
- [6]. Penna G, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009 Apr 1;69(5):480-93. [Content Brief]
- [7]. Foreback JL, et al. Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway. J Leukoc Biol. 1998 Jul;64(1):124-33. [Content Brief]
- [8]. Speer EM, et al. Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro. PLoS One. 2018 May 1;13(5):e0196352. [Content Brief]
-
IL-5 Related Products (33)
Related Products (33)
-
Recombinant Proteins (20)
- 1
- 2
-
Lyn peptide inhibitor
0 ImagesLyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy.
-
Lasrekibart
0 ImagesCat. No.: HY-P991144CAS No.: 3021525-26-5Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma.
-
Revbekitug
0 ImagesCat. No.: HY-P991712CAS No.: 3031358-43-4
-
1,1′-Ethylidenebis[L-tryptophan]
![1,1′-Ethylidenebis[L-tryptophan]](https://file.medchemexpress.com/product_pic/hy-w585843.gif "Click to View 1,1′-Ethylidenebis[L-tryptophan] Product Detail")
0 ImagesCat. No.: HY-W585843CAS No.: 132685-02-01,1′-Ethylidenebis[L-tryptophan] is an orally active amino acid analog. 1,1′-Ethylidenebis[L-tryptophan] promotes the release of adrenocorticotropic hormone and corticosterone in rat plasma, and transiently inhibits CRH mRNA in the paraventricular nucleus of the hypothalamus via glucocorticoid negative feedback. 1,1′-Ethylidenebis[L-tryptophan] induces multi-tissue inflammation and fibrosis in rodents and human cells, increases the number of degranulated mast cells, and activates the IL-5 pathway in lymphocytes. 1,1′-Ethylidenebis[L-tryptophan] is activated by tryptophanyl-tRNA synthetase and replaces L-tryptophan during translation; it also interferes with tryptophan metabolism in mice via the kynurenine pathway and dynamically alters their plasma quinolinic acid levels. 1,1′-Ethylidenebis[L-tryptophan] can be used for studies on metabolism-related mechanisms.
-
AN-2898
0 ImagesCat. No.: HY-111167CAS No.: 906673-33-4AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research.
-
SHR-1703
0 ImagesCat. No.: HY-P991599SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
-
AVP-13358
0 ImagesCat. No.: HY-165484CAS No.: 459805-03-9AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses.
-
Lyn peptide inhibitor TFA
0 ImagesCat. No.: HY-P1111ALyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders.
-
Olcorolimus
0 ImagesCat. No.: HY-106979CAS No.: 186752-78-3Synonyms: SAR-943Olcorolimus (SAR-943) is a Rapamycin (HY-10219) derivative. Olcorolimus can reduce IL-4, IL-5, eosinophil, neutrophil, lymphocyte, cellular fibronectin; lung epithelial cell proliferation and mucus hypersecretory phenotype in Ovalbumin (HY-W250978)-sensitized BALB/c mice. Olcorolimus can be used for the researches of inflammation and immunology, such as asthma.
-
ANB032
0 ImagesCat. No.: HY-P992182ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
-
Aloin (mixture of A&B) (Standard)
0 ImagesAloin (mixture of A&B) (Standard) is the analytical standard of Aloin (mixture of A&B) (HY-N6013). This product is intended for research and analytical applications. Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma.
-
RPR-106541
0 ImagesCat. No.: HY-19218CAS No.: 159001-35-1RPR-106541 is a 17-thiosteroid. RPR 106541 has potent glucocorticosteroid activity. RPR 106541 also has demonstrable effects on carbohydrate and lipid metabolism.
- 1
- 2
